entertainment -WSS

entertainment

author：focus 2025-09-14 10:05:20 - browse：72435

The FDA building -- First Opinion coverage from STAT — Adobe

U.S. regulators on Wednesday approved the first treatment for an ultra-rare disease that causes people to grow bone where it otherwise shouldn’t be, extending an option to patients who have been advocating for access to the medicine.

The treatment, an oral medication that will be marketed as Sohonos, faced some questions about the quality of its data, and was rejected earlier this year by European regulators. But in approving the drug for the treatment of fibrodysplasia ossificans progressiva, or FOP, the Food and Drug Administration concluded that Sohonos’ benefits outweigh its risks.

“I just closed my eyes and looked up to the skies, like ‘Thank you, God,’” said Suzanne Hollywood, whose teenage son, Joey, has been receiving the drug in a clinical trial. “It’s far from perfect, but I’m thrilled for my son, for his future, and for the kids getting diagnosed who might not have to experience what others had to.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

focus

WSS

Covid vaccine financial winners and losers, from Pfizer to Novavax

Roche subsidiary Foundation Medicine opens new headquarters

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Providers still hesitate to prescribe buprenorphine, study finds

HIPAA doesn't protect reproductive records from prosecutors

explore

entertainment

leisure time

Duchenne breakthrough therapy leaves behind pioneering families

Merck drug for rare lung condition set for approval in U.S.

Affirmative action in medical school literally saved lives

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Drug repurposing or repositioning? The language matters

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

States should stop sabotaging methadone treatment reform

In Memoriam: Notable people who died in 2023

Supreme Court mifepristone arguments center on docs' right to sue

hotspot

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Decaf coffee targeted by food safety group under obscure FDA rule

Abortion pill Supreme Court ruling could impact entire drug industry

FDA's naming rule on biosimilars has undermined competition

Death toll from an explosion and collapse of a Paris building in June climbs to 3

focus

knowledge

focus

focus